BRIEF published on 05/23/2024 at 09:17, 3 months 27 days ago Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 Cancer Treatment Conférences Heidelberg Pharma HDP-101 ADCs
PRESS RELEASE published on 05/23/2024 at 09:12, 3 months 27 days ago Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 Heidelberg Pharma AG to participate and present at leading scientific conferences in May and June 2024, showcasing innovative ADC technology platforms for cancer treatment Cancer Treatment ADC Technology Heidelberg Pharma AG Scientific Conferences Clinical Stage Biotech
BRIEF published on 04/25/2024 at 07:26, 4 months 24 days ago Heidelberg Pharma AG publie ses résultats financiers et ses progrès opérationnels pour le premier trimestre 2024 Performance Financière Nomination Du PDG Heidelberg Pharma SA Essai Clinique HDP-101 Développement Du Pipeline ADC
BRIEF published on 04/25/2024 at 07:26, 4 months 24 days ago Heidelberg Pharma AG Reports on Q1 2024 Financials and Operational Progress Financial Performance CEO Appointment Heidelberg Pharma AG HDP-101 Clinical Trial ADC Pipeline Development
PRESS RELEASE published on 04/25/2024 at 07:21, 4 months 24 days ago Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 Heidelberg Pharma AG reports on its interim management statement for the first three months of 2024, including first efficacy data from a clinical trial and successful financing activities Clinical Trial Heidelberg Pharma AG ADC Pipeline Interim Statement Financing Activities
BRIEF published on 04/05/2024 at 09:35, 5 months 14 days ago Heidelberg Pharma organisera un webinaire R&D pour partager de nouvelles informations sur la recherche sur le cancer Heidelberg Pharma HDP-101 Myélome Multiple ADC Webinaire R&D
BRIEF published on 04/05/2024 at 09:35, 5 months 14 days ago Heidelberg Pharma to Convene R&D Webinar to Share New Cancer Research Insights Heidelberg Pharma HDP-101 Multiple Myeloma ADCs R&D Webinar
PRESS RELEASE published on 04/05/2024 at 09:30, 5 months 14 days ago Heidelberg Pharma to host R&D Webinar following novel data presented at AACR Heidelberg Pharma AG to host R&D Webinar on 23 April 2024 featuring leading Key Opinion Leaders after presenting novel data at AACR. Event focuses on ADC technologies for cancer treatment Cancer Treatment Heidelberg Pharma AG R&D Webinar ADC Technologies AACR
BRIEF published on 03/27/2024 at 09:06, 5 months 23 days ago Heidelberg Pharma obtient la désignation de médicament orphelin par la FDA pour le HDP-101 dans le traitement du myélome multiple FDA Heidelberg Pharma Désignation De Médicament Orphelin HDP-101 Myélome Multiple
BRIEF published on 03/27/2024 at 09:06, 5 months 23 days ago Heidelberg Pharma Obtains FDA Orphan Drug Designation for HDP-101 in Multiple Myeloma Treatment FDA Orphan Drug Designation Heidelberg Pharma HDP-101 Multiple Myeloma
Published on 09/19/2024 at 23:15, 22 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 37 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 20:15, 3 hours 22 minutes ago Living Security Named a Leader in Human Risk Management, Closely Watched Tech Industry Report
Published on 09/19/2024 at 21:09, 2 hours 27 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 4 hours 53 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 5 hours 34 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 5 hours 45 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 5 hours 45 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 5 hours 52 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 5 hours 52 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 5 hours 52 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)